{"id":"ulo","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Gout flare"},{"rate":null,"effect":"Renal-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL1652087","moleculeType":"Small molecule","molecularWeight":"446.46"},"_dailymed":{"setId":"54de10ef-fe5f-4930-b91d-6bbb04c664bd","title":"ULORIC (FEBUXOSTAT) TABLET [TAKEDA PHARMACEUTICALS AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ULO works by blocking the urate transporter URAT1 in the proximal tubule of the kidney, preventing reabsorption of filtered uric acid and promoting its elimination in urine. This mechanism lowers serum uric acid levels without inhibiting xanthine oxidase, making it suitable for patients who cannot tolerate or have contraindications to xanthine oxidase inhibitors.","oneSentence":"ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:06:53.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic gout management and serum uric acid lowering"}]},"trialDetails":[{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT07305831","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-22","conditions":"Healthy","enrollment":62},{"nctId":"NCT07334886","phase":"PHASE1","title":"A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-17","conditions":"Healthy","enrollment":8},{"nctId":"NCT06891066","phase":"PHASE2","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-14","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":138,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-8507","Ulonivirine.","ulonivirine"],"phase":"marketed","status":"active","brandName":"ULO","genericName":"ULO","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption. Used for Chronic gout management and serum uric acid lowering.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}